# Cardiovascular and Renal Drugs Advisory Committee; Amendment of Notice
**AGENCY:**
Food and Drug Administration, HHS.
**ACTION:**
Notice.
The Food and Drug Administration (FDA) is announcing an amendment to the notice of a meeting of the Cardiovascular and Renal Drugs Advisory Committee. This meeting was announced in the *Federal Register* of August 14, 2007 (72 FR 45435). The amendment is being made to reflect a change in the *Date and Time* and *Agenda* portions of the meeting. There are no other changes.
**FOR FURTHER INFORMATION CONTACT:**
Cathy A. Miller, Center for Drug Evaluation and Research (HFD-21), Food and Drug Administration, 5630 Fishers Lane (for express delivery, 5630 Fishers Lane, rm. 1093), Rockville, MD 20857, 301-827-7001, FAX: 301-827-6776, e-mail: *[email protected]* , or FDA Advisory Committee Information Line, 1-800-741-8138 (301-443-0572 in the Washington, DC area), code 3014512533. Please call the Information Line for up-to-date information on this meeting.
**SUPPLEMENTARY INFORMATION:**
In the *Federal Register* of August 14, 2007, FDA announced that a meeting of the Cardiovascular and Renal Drugs Advisory Committee would be held on October 16 and 17, 2007.
On page 45435, in the second column, the *Date and Time* portion of the document is amended to read as follows:
*Date and Time* : The meeting will be held on October 16, 2007, from 8 a.m. to 5 p.m.
On page 45435, in the third column, the *Agenda* portion of the document is amended to read as follows:
*Agenda* : On October 16, 2007, the committee will discuss regulatory considerations for extending the use of phosphate binders from the dialysis population (where they are approved) to the pre-dialysis population (where no products are approved). The committee will hear presentations on this topic from Shire Development, Genzyme Corp., and Fresenius Medical Care.
Dated: September 5, 2007.
Randall W. Lutter,
Deputy Commissioner for Policy.